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Summary
One hundred fifty-two families with prostate cancer
were analyzed for linkage to markers spanning a 20-cM
region of 1q42.2-43, the location of a putative prostate
cancer–susceptibility locus (PCAP). No significant evi-
dence for linkage was found, by use of both parametric
and nonparametric tests, in our total data set, which
included 522 genotyped affected men. Rejection of link-
age may reflect locus heterogeneity or the confounding
effects of sporadic disease in older-onset cases; therefore,
pedigrees were stratified into homogeneous subsets
based on mean age at diagnosis of prostate cancer and
number of affected men. Analyses of these subsets also
detected no significant evidence for linkage, although
LOD scores were positive at higher recombination frac-
tions, which is consistent with the presence of a small
proportion of families with linkage. The most suggestive
evidence of linkage was in families with at least five
affected men (nonparametric linkage score of 1.2; P 
). If heterogeneity is assumed, an estimated 4%–9%.1
of these 152 families may show linkage in this region.
We conclude that the putative PCAP locus does not ac-
count for a large proportion of these families with pros-
tate cancer, although the linkage of a small subset is
compatible with these data.
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Introduction
A variety of studies—including case-control, family, and
twin studies (Ross et al. 1987; Steinberg et al. 1990;
Gro¨nberg et al. 1994; Whittemore et al. 1995)—and
segregation analyses have suggested strong evidence for
an inherited component to prostate cancer susceptibility.
Whereas data from one population-based cohort study
are most consistent with an X-linked or recessive model
of inheritance of susceptibility genes (Monroe et al.
1995), three independent segregation analyses (Carter et
al. 1992; Gro¨nberg et al. 1997a; Schaid et al. 1998)
supported an autosomal dominant model of prostate
cancer inheritance. Dominant alleles are estimated to
have a low population frequency (0.3%–1.67%) and to
account for ∼9% of all cases of prostate cancer by 85.0
years of age and for as much as 43% of cases of disease
among men affected at !55.0 years of age (Carter et al.
1992; Gro¨nberg et al. 1997a; Schaid et al. 1998). Im-
portantly, there is strong evidence from these studies that
such genes are likely to have high lifetime penetrances
of 63%–89%.
Analyses of candidate genes that may be involved in
prostate cancer initiation or progression have included
genes involved in the normal regulation of prostatic cells,
such as the androgen-receptor gene, and other known
tumor-suppressor genes, including P53, PTEN, and
BRCA1. There is evidence that polymorphisms within
the coding regions of some genes, including the vitamin
D and androgen-receptor genes, may modify risk (Irvine
et al. 1995; Taylor et al. 1996; Giovannucci et al. 1997;
Ingles et al. 1997; Stanford et al. 1997), and loss-of-
heterozygosity and mutation-detection studies have sug-
gested a role for known tumor suppressors in the pro-
gression of sporadic tumors (Cairns et al. 1997; Feilotter
et al. 1998). To date, however, no obvious candidate
gene has emerged as a major component of inherited
risk, suggesting that other, unidentified loci determine
prostate cancer susceptibility.
One strategy for the identification of susceptibility loci
of unknown function uses genomewide screens of high-
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risk families, with polymorphic markers analyzed by
LOD linkage methods. However, the etiology of prostate
cancer is such that the disease does not readily lend itself
to these types of analyses, for two reasons. First, prostate
cancer is a late onset, often undiagnosed disease; !5%
of diagnoses are in men !55.0 years of age (Stanford et
al., in press). This reduces the availability of genotypic
information from multiple generations of affected men
and necessitates analysis of large numbers of families,
to achieve sufficient power to detect linkage. Second,
prostate cancer is a very common disease (∼184,500 new
diagnoses in the United States in 1997 [Landis et al.
1998]) with complex inheritance and is expected to ex-
hibit both locus heterogeneity and sporadic disease. In
the absence of refined clinical or epidemiological criteria
to stratify cases on the basis of different kinds of prostate
tumors or, alternatively, the identification of subsets of
families that likely share a single founder effect, the eti-
ologic heterogeneity may confound linkage analysis and
may cause the identification of any single locus to be
problematic. To date, no prostate cancer–susceptibility
gene has been isolated by positional cloning. Neverthe-
less, some promising regions have been identified by
means of genomewide screens, suggesting that the ap-
proach is valid.
The first prostate cancer–susceptibility locus localized
by linkage analysis was HPC1 on chromosome 1q24-
25 (Smith et al. 1996). Heterogeneity analysis suggested
that this locus accounted for disease segregation in 34%
of families with high risk of prostate cancer, in the orig-
inal data set of 91 North American and Swedish families.
Further analysis of an expanded data set suggested that
the majority of families with linkage were those with an
early age at diagnosis, with the proportion of families
with linkage rising to 66% among 14 families with a
mean age at diagnosis of !60.0 years (Gro¨nberg et al.
1997b).
Efforts to confirm this result in other data sets have
produced mixed results, with some studies supporting
linkage (Cooney et al. 1997; Hsieh et al. 1997) and
others finding no evidence for linkage (McIndoe et al.
1997; Berthon et al. 1998; Eeles et al. 1998; authors’
unpublished data). In aggregate, these results suggest
that issues related to locus heterogeneity and HPC1 are
not well understood. Multiple analyses have estimated
that the proportion of families with linkage to HPC1 is
!10%, rather than the original estimate of 34%, sup-
porting the hypothesis that multiple susceptibility loci
affect prostate cancer risk (McIndoe et al. 1997; Berthon
et al. 1998; Eeles et al. 1998; authors’ unpublished data).
The second reported prostate cancer–susceptibility
gene, PCAP, was localized to 1q42.2-43, by Berthon et
al. (1998). An analysis of 47 families of French and
German origin, with a mean of 3.3 affected men per
family, suggested linkage to this region, with a maximum
two-point LOD score of 2.7 with marker D1S2785 and
a nonparametric linkage (NPL) score of 3.1 ( ).P  .001
Heterogeneity analysis suggested that the proportion of
families with linkage to the locus was as much as 50%.
A stratified analysis of nine families with age at diagnosis
!60.0 years in the final generation gave significant mul-
tipoint LOD and NPL scores of 3.3 ( ; BerthonP  .001
et al. 1998).
Confirmation and calculation of the overall contri-
bution of this second locus to hereditary prostate cancer
will be determined by analysis of additional data sets.
We report here the analysis of 152 families with high
risk of prostate cancer, including 522 genotyped men
with prostate cancer, for linkage to this region.
Methods
Family Ascertainment and Confirmation of Diagnosis
Families with high risk of prostate cancer were re-
cruited nationally as part of the ongoing Prostate Cancer
Genetic Research Study (PROGRESS) initiated in 1995.
All families met at least one of three criteria: three or
more first-degree affected relatives, prostate cancer in
three generations, or two affected siblings with prostate
cancer diagnosed at 60.0 years of age. Blood samples
and medical and demographic information, including
family history of cancer, were provided by affected men
and selected unaffected male and female family mem-
bers. In addition, consent to access medical records re-
lated to the diagnosis and treatment of cancer was re-
quested. All study procedures and forms were approved
by the institutional review board of the Fred Hutchinson
Cancer Research Center. Detailed procedures for the
contacting of families, the selection of individuals for
collection, and the isolation of DNA have been sum-
marized elsewhere (McIndoe et al. 1997).
Diagnoses of prostate cancer in sampled affected men
were made during 1974–97. Medical records were re-
ceived for 494 (94.6%) of 522 genotyped affected men.
The medical records for all but 1 man confirmed the
prostate cancer diagnosis.
Markers and Genotyping
The 1q42-43 markers used were D1S235–11.63 cM–
D1S2785–1.24 cM–D1S547–8.26 cM–D1S1609. Sex-
averaged distances are from genetic maps from the
Marshfield Medical Research Foundation. PCR ampli-
fications incorporated an infrared dye (IRD40-dATP
[Boehringer Mannheim] or IRD700-dATP [Enzo/LI-
COR]) and were analyzed on LICOR 4200 automated
sequencing machines, as described elsewhere (McIndoe
et al. 1997). Because many pedigrees contained ungeno-
typed founders, allele frequencies were estimated from
all genotyped individuals. We expected, given 152 fam-
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Table 1
Characteristics of 152 PROGRESS Families
GROUP TOTAL
NO. OF SAMPLED MEN, BY FAMILY MEAN AGE
AT DIAGNOSIS
!66.0 Years !61.0 Years
White Nonwhite White Nonwhite
Families 152 67 4 20 1
Affected men (range,
per family) 648 (3–9) 281 (3–9) 26 (4–9) 79 (3–6) 4
Genotyped affected men
(range, per family) 522 (2–7) 231 (2–5) 20 (3–7) 64 (2–5) 3
ilies, that these frequencies would approximate the true
population frequencies (Terwilliger and Ott 1994), not
accounting for any racial differences. The derived fre-
quencies closely corresponded to allele frequencies in the
Genome Database.
Linkage Analysis
Two-point parametric analyses were performed with
the ANALYZE software package (Terwilliger 1996) and
LINKAGE, version 5.1 (Lathrop et al. 1984). Multipoint
parametric and nonparametric analyses used GENE-
HUNTER, version 1.2 (Kruglyak et al. 1996). Three
autosomal dominant parametric models were used. The
first, referred to as “S1,” was based on the segregation-
analysis data of Carter et al. (1992) and has been de-
scribed elsewhere (McIndoe et al. 1997). Models B1 and
B2 are identical to models 1 and 2 used by Berthon et
al. (1998) to identify the original linkage to the 1q42.2-
43 region. For purposes of the analyses, affected status
was coded as unknown for men45.0 years of age who
reported being unaffected but who indicated that they
had not had a prostate specific antigen (PSA) test in the
previous 5 years, did not know if they had ever had a
PSA test, or had an elevated or abnormal PSA level but
did not have physician-diagnosed benign prostatic
hyperplasia.
Results
Analysis of 152 Families with High Risk of Prostate
Cancer
To ensure maximum reliability of information, the
pedigrees analyzed included only information from sam-
pled questionnaire respondents or from unsampled fam-
ily members who are first-degree relatives of a ques-
tionnaire respondent. The 152 families included a total
of 648 affected men (range, 3–9 per family; mean, 4.3
per family). The number of genotyped individuals was
1,189, including 522 affected men (range, 2–7 per fam-
ily; mean, 3.4 per family). The mean age at diagnosis of
prostate cancer in the sampled affected men in each fam-
ily was within the range 52.8–78.0 years (mean, 66.7
years; table 1).
Four polymorphic microsatellite markers spanning a
20-cM region of 1q42.2-43 were analyzed, including
D1S2785, which gave the maximum two-point LOD
score in the study by Berthon et al. (1998). Two-point
LOD scores summed across 152 families (table 2) did
not show evidence for linkage, under any model, and
ranged from 8.5 to 52.4 at recombination fraction
(v)  .0. In all cases, the maximum LOD score at any
v was !0.1. Analysis of all 152 families, by means of
multipoint nonparametric methods, resulted in a max-
imum NPL score of 0.23 ( ; table 2). The para-P  .40
metric multipoint LOD scores were highly negative
across the entire region (range, 29.7 to 42.0 for
model S1). A maximum LOD score under the assump-
tion of heterogeneity (HLOD) of 0.054 was found when
a (proportion of families with linkage) was assumed to
be .029.
The six nonwhite families were Native American, Af-
rican American, Latino, or Japanese. No ethnic/racial
group accounted for more than two families; thus, these
groups were not analyzed independently (the total LOD
score for nonwhite families was 1.3 at D1S2785;
LOD scores for individual families ranged from 0.30 to
1.18). Exclusion of these families from the total data
set did not significantly alter the results.
Analysis of Age-Stratified Subsets
Families with a large number of affected individuals
or with individuals affected at an early age may be ex-
pected to be the most likely to have an inherited pre-
disposition to prostate cancer. Stratifications based on
age have proved useful for enriching for families with
linkage to prostate cancer–susceptibility loci (Gro¨nberg
et al. 1997b; Berthon et al. 1998; Gibbs et al. 1999).
The 152 families included in this study can be divided
into subsets of 71 and 81 families, with a mean age for
sampled affected men of !66.0 years and 66.0 years,
respectively (table 1).
Analysis of 67 white families with a mean age at di-
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Table 2
Two-Point and Multipoint Analyses with 1q42.2-43 Markers, for 152 Families
MARKER
DISTANCE
(CM)
TWO-POINT ANALYSIS MULTIPOINT ANALYSIS
LOD Score
at v  .0
Maximum
LOD Score (v)
Maximum
HLOD Score (v) a
LOD
Score
HLOD
Score a
NPL
Score P Value
D1S235 ) 27.706 .000 (.50) .000 (.50) 1.00 36.957 .001 .000 1.347 .914
D1S2785 11.63 30.638 .070 (.40) .168 (.00) .05 42.387 .003 .010 .028 .483
D1S547 1.24 23.518 .078 (.38) .078 (.38) 1.00 42.016 .011 .014 .175 .425
D1S1609 8.26 24.617 .000 (.50) .087 (.00) .05 34.802 .054 .029 .230 .403
NOTE.—Distance is from the preceding marker. LOD scores shown were calculated by use of model S1; other models gave similar results.
Multipoint scores are shown only for positions corresponding to markers.
agnosis among sampled affected men of !66.0 years did
not suggest linkage, for any model, with negative LOD
scores at low v values (data not shown). At , allv  .0
LOD scores, except those with D1S547 and model B2,
were !2.0, which in general is considered to be sig-
nificant evidence against linkage (data not shown). Pos-
itive LOD scores were found at higher v values; the max-
imum LOD score for any marker in the region was 0.32
at , with D1S547 and model S1. Multipoint anal-v  .28
yses also did not support linkage in this subset of fam-
ilies; multipoint LOD scores and model-independent
NPL scores were negative across the entire region, with
a maximum NPL score of 0.286 ( ; data notP  .60
shown).
The most provocative evidence for linkage was found,
by Berthon et al. (1998), in nine families with very early
onset of prostate cancer; therefore, we further restricted
the younger age group to 20 white families with a mean
age at diagnosis of !61.0 years. Analysis of these fam-
ilies, by use of models S1 and B1, gave negative LOD
scores at but gave positive maximum LOD scoresv  .0
at v values of .0–.362 for markers D1S2685, D1S547,
and D1S1609, by use of all three models (table 3). When
model B2 was used, a nonsignificant positive LOD
score was seen with D1S1609 (1.176 at ). Multi-v  .0
point analysis, however, gave no evidence for linkage
(table 4).
Stratification by Number of Affected Men per Family
The 152 families also were stratified by the number
of affected men in each pedigree. The data for 46 white
families with at least five affected men were analyzed.
Although LOD scores were significantly negative at
small v values, LOD scores were positive at D1S2785,
D1S547, and D1S1609 at , for all three modelsv ∼ .3
(table 5). Under the assumption of heterogeneity, LOD
scores at D1S2785 were within the range 0.44–0.47 at
and a  .12–.17 with all three models. LODv  .0
scores at D1S1609 were within the range 0.76–0.90 at
, when a was assumed to be .29–.22 (table 5).v  .0
Multipoint analysis of this group resulted in a maximum
NPL score of 1.23 ( ) at a position correspondingP  .11
to D1S1609 (table 6). Under the assumption of heter-
ogeneity, multipoint LOD scores at this position were
within the range 0.46–0.57 (a of .12–.15).
Given that the strongest evidence for linkage was
found in families with at least five affected men, we next
considered the possibility that the families most likely
to show linkage would be those that shared a young
mean age at onset and a significant number of affected
men. We therefore analyzed the 22 white families with
a mean age at diagnosis of !66.0 years and with at least
five affected men (data not shown). The results were less
suggestive than those described above for the 46 white
families. Under the assumption of heterogeneity, markers
D1S2785, D1S547, and D1S1609 yielded LOD scores
within the range 0.102–0.619 at v values of .0–.26, when
all three models were used. The maximum LOD score
of 0.619 at was observed with D1S547. NPLv  .18
scores were negative across the entire region (data not
shown).
As an additional subset analysis, we selected those six
white families that had at least five affected men and a
mean age at onset of !61.0 years, representing a refined
stratification of families in which disease is most likely
due to genetic causes. With D1S1609, LOD scores were
within the range 0.87–1.11 at , for the three mod-v  .0
els (data not shown). However, no evidence for linkage
was observed at the intervening marker, D1S547, at any
v value, and the maximum NPL score was 0.12
( ; data not shown).P  .5
Exclusion of Families with Potential Linkage to Other
Loci
Currently, there are no defined clinical criteria to dis-
tinguish sporadic from genetic prostate cancer orHPC1-
associated disease from that induced by other suscep-
tibility loci. Until HPC1 is cloned, prediction of the
families potentially with linkage and those potentially
without linkage is only possible on the basis of individual
family LOD scores and haplotype sharing. We previ-
ously had shown that the first 150 PROGRESS families
contain few families with potential linkage to HPC1
(McIndoe et al. 1997; authors’ unpublished data) but
that there is evidence for a rare putative prostate/brain
cancer locus at 1p36 (provisionally termed “CAPB”) in
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Table 3
Two-Point LOD Scores with 1q42.2-43 Markers, for 20 White Families with Mean
Age at Diagnosis !61.0 Years
Model
and Marker
Distance
(cM)
LOD Score
at v  .0
Maximum
LOD Score (v)
Maximum
HLOD Score (v) a
S1:
D1S235 ) 2.720 .000 (.50) .010 (.00) .05
D1S2785 11.63 3.009 .008 (.38) .008 (.38) 1.00
D1S547 1.24 1.424 .112 (.26) .112 (.26) 1.00
D1S1609 8.26 .644 .362 (.16) .429 (.00) .42
B1:
D1S235 ) 3.977 .000 (.50) .011 (.00) .04
D1S2785 11.63 3.997 .048 (.32) .048 (.32) .99
D1S547 1.24 3.150 .073 (.30) .073 (.30) 1.00
D1S1609 8.26 .675 .464 (.16) .542 (.00) .44
B2:
D1S235 ) 1.552 .000 (.50) .000 (.50) 1.00
D1S2785 11.63 .367 .141 (.20) .141 (.20) 1.00
D1S547 1.24 .705 .058 (.26) .058 (.26) 1.00
D1S1609 8.26 1.176 1.176 (.00) 1.176 (.00) 1.00
Table 4
Multipoint Analyses of 20 White Families with Mean Age at Diagnosis !61.0 Years
MARKER
POSITION
PARAMETRIC MODEL
NONPARAMETRIC
S1 B1 B2 MODEL
LOD
Score
HLOD
Score a
LOD
Score
HLOD
Score a
LOD
Score
HLOD
Score a
NPL
Score P Value
0 2.085 .056 .112 3.630 .063 .100 .914 .021 .130 .418 .652
11.63 4.257 .001 .000 6.010 .001 .001 1.336 .002 .004 .229 .578
12.87 3.757 .001 .000 5.364 .001 .001 1.335 .002 .004 .147 .546
19.89 1.611 .123 .234 2.154 .220 .256 .077 .198 .503 .399 .335
NOTE.—Results shown correspond to the positions of the markers described in table 3 (D1S235, D1S2785, D1S547, and D1S1609,
respectively).
a small subset of the PROGRESS families (Gibbs et al.
1999). To minimize the effects of locus heterogeneity on
our analysis, the entire data set was stratified to exclude
families that had greater evidence of linkage to either
the HPC1 or CAPB loci, based on comparison of the
maximum absolute LOD scores at each locus. Eighty-
eight families had stronger evidence of linkage to HPC1
or CAPB, leaving a subset of 64 families that were either
negative at all three loci ( ) or had the greatestn  28
positive score atD1S2785 ( ). When these familiesn  34
were analyzed by use of the four markers that define the
PCAP locus, we observed a maximum LOD score for
D1S2785 of 1.90 at . However, at the closest ad-v  .0
jacent marker,D1S547, a maximum LOD score of 0.365
at was observed, and LOD scores at D1S235v  .28
and D1S1609 also were low (0.0 and 0.038, respec-
tively), suggesting that the result for D1S2785 likely re-
flects bias imposed by stratification based on LOD scores
for that individual marker, rather than identification of
a linked subset.
Therefore, a more conservative stratification to re-
move the families likely to show linkage to CAPB was
the removal of families with a large positive LOD score
at D1S407. A total of eight families that had LOD scores
0.4 (range, 0.43–1.09) at D1S407 were excluded from
the 46 with at least five affected men. Analysis of the
remaining 38 families found LOD scores at D1S1609
that were higher than those observed for the original 46
families (table 5), with all three models (table 7), but
less difference was observed at the other three loci. Sim-
ilarly, multipoint analysis revealed a higher maximum
NPL score of 1.4 ( ) at D1S1609 but less evidenceP  .09
for linkage over the rest of the region (table 7).
Discussion
Analysis of 152 families at high risk for prostate can-
cer found overall evidence against linkage of prostate
cancer to markers at chromosome 1q42.2-43. This re-
jection of linkage to PCAP may reflect locus heteroge-
neity. Pedigrees, therefore, were stratified into homo-
geneous subsets based on race, mean age at diagnosis of
prostate cancer, and number of affected men. Although
analyses of these subsets also did not support linkage,
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Table 5
Two-Point LOD Scores with 1q42.2-43 Markers, for 46 White Families with at
Least Five Affected Men
Model
and Marker
Distance
(cM)
LOD Score
at v  .0
Maximum
LOD Score (v)
Maximum
HLOD Score (v) a
S1:
D1S235 ) 16.276 .000 (.50) .000 (.50) 1.00
D1S2785 11.63 10.493 .403 (.30) .459 (.00) .15
D1S547 1.24 8.271 .229 (.30) .229 (.30) 1.00
D1S1609 8.26 8.133 .432 (.28) .775 (.00) .23
B1:
D1S235 ) 24.739 .000 (.50) .000 (.50) 1.00
D1S2785 11.63 18.827 .412 (.32) .469 (.00) .12
D1S547 1.24 15.258 .098 (.36) .098 (.36) 1.00
D1S1609 8.26 14.635 .288 (.32) .900 (.00) .22
B2:
D1S235 ) 10.103 .000 (.50) .000 (.50) 1.00
D1S2785 11.63 5.326 .307 (.30) .441 (.00) .17
D1S547 1.24 4.883 .087 (.32) .087 (.32) .94
D1S1609 8.26 3.044 .378 (.26) .758 (.00) .29
Table 6
Multipoint Analysis of 46 White Families with at Least Five Affected Men
MARKER
POSITION
PARAMETRIC MODEL
NONPARAMETRIC
S1 B1 B2 MODEL
LOD
Score
HLOD
Score a
LOD
Score
HLOD
Score a
LOD
Score
HLOD
Score a
NPL
Score P Value
0 18.868 .000 .000 28.084 .000 .000 11.512 .000 .000 .936 .824
11.63 15.871 .192 .068 26.047 .188 .055 8.687 .195 .085 1.034 .151
12.87 15.148 .192 .069 25.007 .182 .055 8.855 .177 .080 1.009 .156
19.89 11.379 .569 .145 19.067 .571 .121 6.369 .461 .152 1.228 .113
NOTE.—Results shown correspond to the positions of the markers described in table 5 (D1S235, D1S2785, D1S547, and D1S1609,
respectively).
positive—albeit small—LOD scores were found at larger
v values (in general, 1.2). This is the pattern expected
when a small proportion of families have linkage to the
region of interest. The most suggestive evidence for link-
age was in those families with at least five affected men,
although statistical significance was not achieved. The
estimated a in this subset of 46 families was .12–.29,
corresponding to ∼4%–9% of the total data set of 152
families. Given the overall lack of significance and the
model dependence of these estimates, however, this result
should be treated with caution. Further stratification of
this group by mean age at diagnosis did not improve
the evidence for linkage. As expected from the size and
structure of the pedigrees analyzed, no single family gen-
erated a significant LOD score. The most suggestive was
a family with a mean age at diagnosis of 67.0 years,
which had a maximum LOD score of 1.3 at D1S2785
and a maximum NPL score of 5.03 ( ), unad-P  .004
justed for 152 comparisons.
The original report of linkage between inherited pros-
tate cancer and 1q42.2-43 was found by analysis of 47
families. These families included 194 genotyped individ-
uals, of whom 122 were affected, for an average of 2.6
affected individuals per family (Berthon et al. 1998). The
proportion of families with linkage was estimated to be
50%. The 152 families analyzed here included 1,189
genotyped individuals, including 522 genotyped affected
men, for an average of 3.4 affected men per family. It
is likely, therefore, that linkage of the magnitude seen
by Berthon et al. (1998) could be detected in our data
set. Berthon et al. (1998) noted, however, that the pro-
portion of families with linkage of 50% was likely to
be an overestimate, given the number of families with
only two informative meioses, and they suggested a
lower figure of 20%, based on the proportion of families
with early onset.
SIMLINK analyses performed on subsets of PRO-
GRESS families, under the assumptions of marker in-
formativeness (polymorphic information content [PIC])
of .7, penetrance of 88% for carriers, and penetrance of
5% for noncarriers, suggested sufficient power to detect
linkage if, as estimated by Berthon et al. (1998), 50%
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Table 7
Two-Point and Multipoint Analyses for 38 Families with at Least Five Affected Men and LOD Scores !0.4 at the CAPB Locus
MARKER
DISTANCE
(CM)
TWO-POINT ANALYSIS MULTIPOINT ANALYSIS
LOD Score
at v  .0
Maximum
LOD Score (v)
Maximum
HLOD Score (v) a
LOD
Score
HLOD
Score a
NPL
Score P Value
D1S235 ) 6.514 .000 (.50) .216 (.46) .71 15.935 .000 .000 .776 .775
D1S2785 11.63 10.882 .149 (.34) .150 (.34) .92 14.691 .096 .046 .656 .245
D1S547 1.24 6.513 .216 (.30) .216 (.30) 1.00 13.683 .105 .050 .686 .237
D1S1609 8.26 4.868 .708 (.24) 1.214 (.00) .33 8.245 .840 .202 1.396 .088
NOTE.—Distance is from the preceding marker. LOD scores shown were calculated by use of model S1; other models gave similar results.
Multipoint scores are shown only for positions corresponding to markers.
of the families show linkage (G. P. Jarvik, J. L. Stanford,
E. L. Goode, L. Hood, E. A. Ostrander, unpublished
data). These estimates are conservative for the analysis
at PCAP, because the 1q24-25 markers analyzed in this
study had PIC values .7. If 30% of families overall
show linkage, the expected LOD scores at andv  .00
.05 are estimated to be 0.286 and 0.297, respectively. If
10% of families show linkage, the expected LOD scores
at and .05 are estimated to be 0.116 and 0.137,v  .00
respectively. We estimate, therefore, that if !10% of fam-
ilies show linkage, the power to detect linkage with a
significant LOD score is low, but a positive overall LOD
score would be expected. Instead, large negative LOD
scores were seen. Therefore, the fact that some stratified
subsets of these families gave low positive LOD scores
is consistent with the notion that a small proportion of
families that have at least five affected men are likely to
have disease due to germ-line mutations at PCAP. In
contrast, our linkage analysis of the HPC1 region, with
the same subset of families, found consistently negative
LOD scores (authors’ unpublished data), suggesting very
little evidence for linkage at the HPC1 locus.
It is difficult to compensate for locus heterogeneity by
stratification, in the absence of defined characteristics to
classify HPC1 or PCAP families. Segregation of families
on the basis of LOD scores or haplotype sharing should
enrich for families with linkage but will naturally include
false-positive results and exclude false-negative results.
This has been aptly demonstrated by the comparison of
BRCA1 and BRCA2 linkage and mutation-detection re-
sults. In one small analysis of 10 families with a high
risk for breast cancer, all characterized by multipoint
LOD scores of !1.0 at the BRCA1 locus, 3 families
were found to carry germ-line mutations in the BRCA1
gene (Narod et al. 1995). Similarly, not all families with
positive LOD scores at the BRCA1 or BRCA2 locus
appear to carry germ-line mutations in these genes, after
careful examination of the entire coding region by means
of even the most stringent mutation-detection methods
(Ford et al. 1998). The cloning of any prostate can-
cer–susceptibility gene, anxiously awaited by both the
basic science and the clinical communities, or the iden-
tification of a biochemical marker to identify homoge-
neous subsets of families would greatly facilitate further
analyses to define other loci.
The proportion of families in this analysis that appear
to have linkage to the HPC1 and PCAP regions was less
than that predicted from initial estimates of frequency
(Smith et al. 1996; Berthon et al. 1998) and suggests
that other prostate cancer–susceptibility loci, possibly
including the recently identified HPCX locus (Xu et al.
1998), account for disease in most of these families. It
is interesting to consider why both the HPC1 (Smith et
al. 1996) and PCAP (Berthon et al. 1998) loci subse-
quently have not been found to account for a similar
proportion of prostate cancer in other, seemingly similar
data sets (McIndoe et al. 1997; Berthon et al. 1998; Eeles
et al. 1998; authors’ unpublished data). This may simply
reflect the existence of multiple prostate cancer–sus-
ceptibility loci, any one of which may be abundant in
some family collections and much rarer in others, owing
to stochastic variation or subtle differences in the family
collections. Because heterogeneity weakens power to de-
tect linkage, a locus must account for a reasonable pro-
portion of families, to yield significant evidence of link-
age. The exact proportion varies, depending on the
sample. When this is considered, given the fact that the
recent localizations ofHPCX (Xu et al. 1998) andCAPB
(Gibbs et al. 1999) bring the number of putative prostate
cancer–susceptibility loci to four, it is not surprising that
the original estimates of proportions of families with
linkage were substantially higher than those in follow-
up studies of other samples. If the loci had not been well
represented in the original sample (because of chance or
study design), significant evidence for linkage could not
have been shown.
Our data are not inconsistent with a prostate cancer
locus at 1q42.2-43. Rather, any prostate cancer–sus-
ceptibility locus in this region likely accounts for less
than the original estimate of 20%–50% of families with
prostate cancer. The exact proportion of families with
disease that can be attributed to this locus can be de-
termined only when a gene is found and mutation-de-
tection studies are completed.
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